Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Atkins

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
Cancer Investigation|May 29, 2007
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II studyWolfram E Samlowski, James Moon, J Philip Kuebler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer|April 15, 1990
A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association StudyD R White, B L Powell, J B Craig, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignanciesB L Powell, H B Muss, R L Capizzi, et al.
Cancer Genomics & Proteomics|June 7, 2013
Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principleFarid E Ahmed, Nancy C Ahmed, Paul W Vos, et al.
Journal of the National Cancer Institute|December 9, 1997
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancerB Fisher, J Dignam, N Wolmark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2009
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancerThomas E Stinchcombe, Lydia Hodgson, James E Herndon, et al.
Journal of Neuro-Oncology|January 1, 1986
Clinical trial of pyridoxine to reduce vincristine neurotoxicityD V Jackson, E K Pope, R A McMahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
BJU International|November 6, 2009
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urotheliumDaniel P Petrylak, Catherine M Tangen, Peter J Van Veldhuizen, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Cancer Investigation|May 29, 2007
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II studyWolfram E Samlowski, James Moon, J Philip Kuebler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer|April 15, 1990
A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association StudyD R White, B L Powell, J B Craig, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignanciesB L Powell, H B Muss, R L Capizzi, et al.
Cancer Genomics & Proteomics|June 7, 2013
Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principleFarid E Ahmed, Nancy C Ahmed, Paul W Vos, et al.
Journal of the National Cancer Institute|December 9, 1997
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancerB Fisher, J Dignam, N Wolmark, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2009
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancerThomas E Stinchcombe, Lydia Hodgson, James E Herndon, et al.
Journal of Neuro-Oncology|January 1, 1986
Clinical trial of pyridoxine to reduce vincristine neurotoxicityD V Jackson, E K Pope, R A McMahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
BJU International|November 6, 2009
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urotheliumDaniel P Petrylak, Catherine M Tangen, Peter J Van Veldhuizen, et al.
Pageof 21